Ascenta Capital — Full Portfolio

4 tracked investments · listed companies and verified rows first

Abata TherapeuticsDec 2023SEC filingmedium confidence

BiotechCambridge, US

SAMANTHA SINGER(Executive Officer, Director)ABBIE CELNIKER(Director)MITCH FINER(Director)NAGESH MAHANTHAPPA(Director)LORENCE KIM(Director)SANDY LAZZARI(Executive Officer)

Board seatLorence Kim· per SEC Form D · filed Dec 2023

ADARx Pharmaceuticals, Inc.Aug 2023SEC filingmedium confidence

San Diego, US

Board seatLorence Kim· per SEC Form D · $200M raise · filed Aug 2023

Odyssey Therapeuticsodysseytx.comin 𝕏Dec 2023SEC filingmedium confidence

Creating next generation precision medicines for patients with cancer and inflammatory diseases by targeting key signaling nodes.

BiotechCambridge, US

Valerie Odegard(Director)Jill Carroll(Director)Carl Gordon(Director)Jeffrey Leiden(Director)Charles Baum(Director)Gary D Glick(Executive Officer, Director)

Board seatLorence Kim· per SEC Form D · $121.1M raise · filed Aug 2024

Santi TherapeuticsDec 2025SEC filingmedium confidence

BiotechWaltham, US

Joshua Resnick(Director)David Grayzel(Director)Milind Deshpande(Executive Officer, Director)Simon Read(Director)

Board seatLorence Kim· per SEC Form D · $120.1M raise · filed Dec 2025

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.